Review



parental hcc cells  (Celprogen Inc)


Bioz Verified Symbol Celprogen Inc is a verified supplier
Bioz Manufacturer Symbol Celprogen Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Celprogen Inc parental hcc cells
    Fig. 1 Characterization of Cancer Stem Cells from human <t>HCC</t> tissues. (A) Real-time analysis of Oct 4, CD 133, Nestin, telom- erase, SSEA-4, AFP and CEA mRNA expres- sion in HCC stem cell under self-renewal con- dition (HSC-SR), under differentiation (HSC- DF) and HepG2 <t>HCC</t> <t>cells.</t> All the markers are significantly up-regulated in HCC cancer stem cells. *P 0.05 when compared with HepG2 group. (B) FACS analysis of HCC stem cells on day 1 before cell sorting. Results are given as the percentage of Oct-4 and CD133
    Parental Hcc Cells, supplied by Celprogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/parental hcc cells/product/Celprogen Inc
    Average 90 stars, based on 4 article reviews
    parental hcc cells - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Functional analysis of microRNAs in human hepatocellular cancer stem cells."

    Article Title: Functional analysis of microRNAs in human hepatocellular cancer stem cells.

    Journal: Journal of cellular and molecular medicine

    doi: 10.1111/j.1582-4934.2011.01282.x

    Fig. 1 Characterization of Cancer Stem Cells from human HCC tissues. (A) Real-time analysis of Oct 4, CD 133, Nestin, telom- erase, SSEA-4, AFP and CEA mRNA expres- sion in HCC stem cell under self-renewal con- dition (HSC-SR), under differentiation (HSC- DF) and HepG2 HCC cells. All the markers are significantly up-regulated in HCC cancer stem cells. *P 0.05 when compared with HepG2 group. (B) FACS analysis of HCC stem cells on day 1 before cell sorting. Results are given as the percentage of Oct-4 and CD133
    Figure Legend Snippet: Fig. 1 Characterization of Cancer Stem Cells from human HCC tissues. (A) Real-time analysis of Oct 4, CD 133, Nestin, telom- erase, SSEA-4, AFP and CEA mRNA expres- sion in HCC stem cell under self-renewal con- dition (HSC-SR), under differentiation (HSC- DF) and HepG2 HCC cells. All the markers are significantly up-regulated in HCC cancer stem cells. *P 0.05 when compared with HepG2 group. (B) FACS analysis of HCC stem cells on day 1 before cell sorting. Results are given as the percentage of Oct-4 and CD133

    Techniques Used: FACS

    Fig. 4 HCC stem cells are resistant to con- ventional chemotherapy. (A, C) After serum starvation of cultured cells overnight, sorafenib and doxorubicin were added at various concentrations (10 3–10 10 M) and cell viability was assessed after 72 hrs. IC50 graph of high-content image analysis of human hepatocytes and HCC stem cells treated by sorafenib and doxorubicin was illustrated. Quantitative data of MTS assay in the sorafenib treated cells were calcu- lated for IC50 with XLfit software, which is marked in the middle of the box. (B, D) IC50 of sorafenib and doxorubicin in hepato- cytes and HCC stem cells is illustrated in bar graph. HCC stem cells under either self- renewal (HSC-SR) or differentiation (HSC- DF) are more resistance to sorafenib and doxorubicin than HepG2 cells and normal liver stem cells. IC50 results are expressed as the mean S.E. of eight different exper- iments. (E) Groups of five SCID Berge mice were selected 8–10 weeks old per treat- ment group. The human HSC-SRs (1000) as well as parental HCC cells (5 106) were injected subcutaneously and allowed to engraft for 10 days. At day 10 the tumour was visible, and then the doxorubicin treat- ment was started and the mice received the desired concentration of the drug intraper- oteneal three times per week for 14 days. At the end of the 14 days the tumour was dis- sociated into single cell suspension and assayed with Almar Blue to determine per- cent inhibition of the drug. (F, G) Differential expression of CD133 and let-7a in vivo following treatment with doxorubicin by real-time PCR is shown. Data represent percentage change in expression in doxo- cibicin-treated tumours compared with controls. *P 0.05 relative to controls.
    Figure Legend Snippet: Fig. 4 HCC stem cells are resistant to con- ventional chemotherapy. (A, C) After serum starvation of cultured cells overnight, sorafenib and doxorubicin were added at various concentrations (10 3–10 10 M) and cell viability was assessed after 72 hrs. IC50 graph of high-content image analysis of human hepatocytes and HCC stem cells treated by sorafenib and doxorubicin was illustrated. Quantitative data of MTS assay in the sorafenib treated cells were calcu- lated for IC50 with XLfit software, which is marked in the middle of the box. (B, D) IC50 of sorafenib and doxorubicin in hepato- cytes and HCC stem cells is illustrated in bar graph. HCC stem cells under either self- renewal (HSC-SR) or differentiation (HSC- DF) are more resistance to sorafenib and doxorubicin than HepG2 cells and normal liver stem cells. IC50 results are expressed as the mean S.E. of eight different exper- iments. (E) Groups of five SCID Berge mice were selected 8–10 weeks old per treat- ment group. The human HSC-SRs (1000) as well as parental HCC cells (5 106) were injected subcutaneously and allowed to engraft for 10 days. At day 10 the tumour was visible, and then the doxorubicin treat- ment was started and the mice received the desired concentration of the drug intraper- oteneal three times per week for 14 days. At the end of the 14 days the tumour was dis- sociated into single cell suspension and assayed with Almar Blue to determine per- cent inhibition of the drug. (F, G) Differential expression of CD133 and let-7a in vivo following treatment with doxorubicin by real-time PCR is shown. Data represent percentage change in expression in doxo- cibicin-treated tumours compared with controls. *P 0.05 relative to controls.

    Techniques Used: Cell Culture, MTS Assay, Software, Injection, Concentration Assay, Suspension, Inhibition, Quantitative Proteomics, In Vivo, Real-time Polymerase Chain Reaction, Expressing



    Similar Products

    sublines hcc lm3 lr  (MedChemExpress)
    92
    MedChemExpress sublines hcc lm3 lr
    Sublines Hcc Lm3 Lr, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sublines hcc lm3 lr/product/MedChemExpress
    Average 92 stars, based on 1 article reviews
    sublines hcc lm3 lr - by Bioz Stars, 2026-03
    92/100 stars
    		  Buy from Supplier
    parental hcc cells  (Celprogen Inc)
    90
    Celprogen Inc parental hcc cells
    Fig. 1 Characterization of Cancer Stem Cells from human <t>HCC</t> tissues. (A) Real-time analysis of Oct 4, CD 133, Nestin, telom- erase, SSEA-4, AFP and CEA mRNA expres- sion in HCC stem cell under self-renewal con- dition (HSC-SR), under differentiation (HSC- DF) and HepG2 <t>HCC</t> <t>cells.</t> All the markers are significantly up-regulated in HCC cancer stem cells. *P 0.05 when compared with HepG2 group. (B) FACS analysis of HCC stem cells on day 1 before cell sorting. Results are given as the percentage of Oct-4 and CD133
    Parental Hcc Cells, supplied by Celprogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/parental hcc cells/product/Celprogen Inc
    Average 90 stars, based on 1 article reviews
    parental hcc cells - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    parental hcc bel-7402 cells  (Nanjing KeyGen Biotech Co Ltd)
    90
    Nanjing KeyGen Biotech Co Ltd parental hcc bel-7402 cells
    Fig. 1 Characterization of Cancer Stem Cells from human <t>HCC</t> tissues. (A) Real-time analysis of Oct 4, CD 133, Nestin, telom- erase, SSEA-4, AFP and CEA mRNA expres- sion in HCC stem cell under self-renewal con- dition (HSC-SR), under differentiation (HSC- DF) and HepG2 <t>HCC</t> <t>cells.</t> All the markers are significantly up-regulated in HCC cancer stem cells. *P 0.05 when compared with HepG2 group. (B) FACS analysis of HCC stem cells on day 1 before cell sorting. Results are given as the percentage of Oct-4 and CD133
    Parental Hcc Bel 7402 Cells, supplied by Nanjing KeyGen Biotech Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/parental hcc bel-7402 cells/product/Nanjing KeyGen Biotech Co Ltd
    Average 90 stars, based on 1 article reviews
    parental hcc bel-7402 cells - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 1 Characterization of Cancer Stem Cells from human HCC tissues. (A) Real-time analysis of Oct 4, CD 133, Nestin, telom- erase, SSEA-4, AFP and CEA mRNA expres- sion in HCC stem cell under self-renewal con- dition (HSC-SR), under differentiation (HSC- DF) and HepG2 HCC cells. All the markers are significantly up-regulated in HCC cancer stem cells. *P 0.05 when compared with HepG2 group. (B) FACS analysis of HCC stem cells on day 1 before cell sorting. Results are given as the percentage of Oct-4 and CD133

    Journal: Journal of cellular and molecular medicine

    Article Title: Functional analysis of microRNAs in human hepatocellular cancer stem cells.

    doi: 10.1111/j.1582-4934.2011.01282.x

    Figure Lengend Snippet: Fig. 1 Characterization of Cancer Stem Cells from human HCC tissues. (A) Real-time analysis of Oct 4, CD 133, Nestin, telom- erase, SSEA-4, AFP and CEA mRNA expres- sion in HCC stem cell under self-renewal con- dition (HSC-SR), under differentiation (HSC- DF) and HepG2 HCC cells. All the markers are significantly up-regulated in HCC cancer stem cells. *P 0.05 when compared with HepG2 group. (B) FACS analysis of HCC stem cells on day 1 before cell sorting. Results are given as the percentage of Oct-4 and CD133

    Article Snippet: Human hepatocellular CSCs and parental HCC cells were provided by Celprogen Inc. (San Pedro, CA, USA).

    Techniques: FACS

    Fig. 4 HCC stem cells are resistant to con- ventional chemotherapy. (A, C) After serum starvation of cultured cells overnight, sorafenib and doxorubicin were added at various concentrations (10 3–10 10 M) and cell viability was assessed after 72 hrs. IC50 graph of high-content image analysis of human hepatocytes and HCC stem cells treated by sorafenib and doxorubicin was illustrated. Quantitative data of MTS assay in the sorafenib treated cells were calcu- lated for IC50 with XLfit software, which is marked in the middle of the box. (B, D) IC50 of sorafenib and doxorubicin in hepato- cytes and HCC stem cells is illustrated in bar graph. HCC stem cells under either self- renewal (HSC-SR) or differentiation (HSC- DF) are more resistance to sorafenib and doxorubicin than HepG2 cells and normal liver stem cells. IC50 results are expressed as the mean S.E. of eight different exper- iments. (E) Groups of five SCID Berge mice were selected 8–10 weeks old per treat- ment group. The human HSC-SRs (1000) as well as parental HCC cells (5 106) were injected subcutaneously and allowed to engraft for 10 days. At day 10 the tumour was visible, and then the doxorubicin treat- ment was started and the mice received the desired concentration of the drug intraper- oteneal three times per week for 14 days. At the end of the 14 days the tumour was dis- sociated into single cell suspension and assayed with Almar Blue to determine per- cent inhibition of the drug. (F, G) Differential expression of CD133 and let-7a in vivo following treatment with doxorubicin by real-time PCR is shown. Data represent percentage change in expression in doxo- cibicin-treated tumours compared with controls. *P 0.05 relative to controls.

    Journal: Journal of cellular and molecular medicine

    Article Title: Functional analysis of microRNAs in human hepatocellular cancer stem cells.

    doi: 10.1111/j.1582-4934.2011.01282.x

    Figure Lengend Snippet: Fig. 4 HCC stem cells are resistant to con- ventional chemotherapy. (A, C) After serum starvation of cultured cells overnight, sorafenib and doxorubicin were added at various concentrations (10 3–10 10 M) and cell viability was assessed after 72 hrs. IC50 graph of high-content image analysis of human hepatocytes and HCC stem cells treated by sorafenib and doxorubicin was illustrated. Quantitative data of MTS assay in the sorafenib treated cells were calcu- lated for IC50 with XLfit software, which is marked in the middle of the box. (B, D) IC50 of sorafenib and doxorubicin in hepato- cytes and HCC stem cells is illustrated in bar graph. HCC stem cells under either self- renewal (HSC-SR) or differentiation (HSC- DF) are more resistance to sorafenib and doxorubicin than HepG2 cells and normal liver stem cells. IC50 results are expressed as the mean S.E. of eight different exper- iments. (E) Groups of five SCID Berge mice were selected 8–10 weeks old per treat- ment group. The human HSC-SRs (1000) as well as parental HCC cells (5 106) were injected subcutaneously and allowed to engraft for 10 days. At day 10 the tumour was visible, and then the doxorubicin treat- ment was started and the mice received the desired concentration of the drug intraper- oteneal three times per week for 14 days. At the end of the 14 days the tumour was dis- sociated into single cell suspension and assayed with Almar Blue to determine per- cent inhibition of the drug. (F, G) Differential expression of CD133 and let-7a in vivo following treatment with doxorubicin by real-time PCR is shown. Data represent percentage change in expression in doxo- cibicin-treated tumours compared with controls. *P 0.05 relative to controls.

    Article Snippet: Human hepatocellular CSCs and parental HCC cells were provided by Celprogen Inc. (San Pedro, CA, USA).

    Techniques: Cell Culture, MTS Assay, Software, Injection, Concentration Assay, Suspension, Inhibition, Quantitative Proteomics, In Vivo, Real-time Polymerase Chain Reaction, Expressing